Oral Cavity Squamous Cell Carcinoma Clinical Trial
Official title:
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Verified date | February 2024 |
Source | NRG Oncology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nodes in your neck. Using sentinel lymph node biopsy surgery may work better in treating patients with early-stage oral cavity cancer compared to standard elective neck dissection.
Status | Recruiting |
Enrollment | 618 |
Est. completion date | May 18, 2036 |
Est. primary completion date | May 18, 2031 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - PRIOR TO STEP 1 REGISTRATION INCLUSION: - Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the oral cavity, including the oral (mobile) tongue, floor of mouth (FOM), mucosal lip, buccal mucosa, lower alveolar ridge, upper alveolar ridge, retromolar gingiva (retromolar trigone; RMT), or hard palate prior to registration - Appropriate stage for study entry (T1-2N0M0; American Joint Committee on Cancer [AJCC] 8th edition [ed.]) based on the following diagnostic workup: - History/physical examination within 42 days prior to registration - Imaging of head and neck within 42 days prior to registration - PET/CT scan or contrast neck CT scan, or gadolinium-enhanced neck magnetic resonance imaging (MRI) or lateral and central neck ultrasound; diagnostic quality CT is preferred and highly recommended for the PET/CT when possible. - Imaging of chest within 42 days prior to registration; chest x-ray, CT chest scan (with or without contrast) or PET/CT (with or without contrast) - Surgical assessment within 42 days prior to registration. Patient must be a candidate for surgical intervention with sentinel lymph node (SLN) biopsy and potential completion neck dissection (CND) or elective neck dissection (END) - Surgical resection of the primary tumor will occur through a transoral approach with anticipation of resection free margins - Zubrod performance status 0-2 within 42 days prior to registration - For women of child-bearing potential, negative serum or urine pregnancy test within 42 days prior to registration - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry - Only patients who are able to read and understand English are eligible to participate as the mandatory patient reported NDII tool is only available in this language - PRIOR TO STEP 2 RANDOMIZATION: - FDG PET/CT required prior to step 2. Note: FDG PET/CT done prior to step 1 can be submitted for central review. - PET/CT node negative patients, determined by central read, will proceed to randomization. - PET/CT node positive patients will go off study, but will be entered in a registry and data will be collected to record the pathological outcome of neck nodes for diagnostic imaging assessment and future clinical trial development - NOTE: All FDG PET/CT scans must be performed on an American College of Radiology (ACR) accredited scanner (or similar accrediting organization) - The patient must complete NDII prior to step 2 registration Exclusion Criteria: - PRIOR TO STEP 1 REGISTRATION EXCLUSION: - Definitive clinical or radiologic evidence of regional (cervical) and/or distant metastatic disease - Prior non-head and neck invasive malignancy (except non-melanomatous skin cancer, including effectively treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix) unless disease free for = 2 years - Diagnosis of head and neck squamous cell carcinoma (SCC) in the oropharynx, nasopharynx, hypopharynx, and larynx - Unable or unwilling to complete NDII (baseline only) - Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable - Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields - Patient with severe, active co-morbidity that would preclude an elective or completion neck dissection - Pregnancy and breast-feeding mothers - Incomplete resection of oral cavity lesion with a positive margin; however, an excisional biopsy is permitted - Prior surgery involving the lateral neck, including neck dissection or gross injury to the neck that would preclude surgical dissection for this trial. Prior thyroid and central neck surgery is permissible; biopsy is permitted. Note: Borderline suspicious nodes that are = 1 cm with radiographic finding suggestive of NOT malignant should be biopsied using ultrasound-guided (U/S-guided) fine-needle aspiration (FNA) biopsy - Underlying or documented history of hematologic malignancy (e.g., chronic lymphocytic leukemia [CLL]) or other active disease capable of causing lymphadenopathy (sarcoidosis or untreated mycobacterial infection) - Actively receiving systemic cytotoxic chemotherapy, immunosuppressive, anti-monocyte or immunomodulatory therapy - Currently participating in another investigational therapeutic trial |
Country | Name | City | State |
---|---|---|---|
Canada | University Health Network-Princess Margaret Hospital | Toronto | Ontario |
United States | University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan |
United States | Emory University Hospital Midtown | Atlanta | Georgia |
United States | Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia |
United States | Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey |
United States | Central Vermont Medical Center/National Life Cancer Treatment | Berlin | Vermont |
United States | Boston Medical Center | Boston | Massachusetts |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | University of Vermont and State Agricultural College | Burlington | Vermont |
United States | University of Vermont Medical Center | Burlington | Vermont |
United States | Northwestern University | Chicago | Illinois |
United States | Rush University Medical Center | Chicago | Illinois |
United States | Clackamas Radiation Oncology Center | Clackamas | Oregon |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
United States | Memorial Sloan Kettering Commack | Commack | New York |
United States | MD Anderson in The Woodlands | Conroe | Texas |
United States | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables | Florida |
United States | Geisinger Medical Center | Danville | Pennsylvania |
United States | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach | Florida |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | Wayne State University/Karmanos Cancer Institute | Detroit | Michigan |
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
United States | Sanford Broadway Medical Center | Fargo | North Dakota |
United States | Sanford Roger Maris Cancer Center | Fargo | North Dakota |
United States | Weisberg Cancer Treatment Center | Farmington Hills | Michigan |
United States | Memorial Sloan Kettering Westchester | Harrison | New York |
United States | Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania |
United States | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston | Texas |
United States | M D Anderson Cancer Center | Houston | Texas |
United States | MD Anderson West Houston | Houston | Texas |
United States | Michael E DeBakey VA Medical Center | Houston | Texas |
United States | University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Iowa |
United States | University of Kansas Cancer Center | Kansas City | Kansas |
United States | UC San Diego Moores Cancer Center | La Jolla | California |
United States | Northwell Health/Center for Advanced Medicine | Lake Success | New York |
United States | MD Anderson League City | League City | Texas |
United States | University of Kentucky/Markey Cancer Center | Lexington | Kentucky |
United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
United States | Saint Barnabas Medical Center | Livingston | New Jersey |
United States | The James Graham Brown Cancer Center at University of Louisville | Louisville | Kentucky |
United States | Methodist Hospital | Memphis | Tennessee |
United States | University of Tennessee Health Science Center | Memphis | Tennessee |
United States | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami | Florida |
United States | Memorial Sloan Kettering Monmouth | Middletown | New Jersey |
United States | NYU Winthrop Hospital | Mineola | New York |
United States | Memorial Sloan Kettering Bergen | Montvale | New Jersey |
United States | Vanderbilt University/Ingram Cancer Center | Nashville | Tennessee |
United States | Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey |
United States | Yale University | New Haven | Connecticut |
United States | Long Island Jewish Medical Center | New Hyde Park | New York |
United States | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York | New York |
United States | Lenox Hill Hospital | New York | New York |
United States | Manhattan Eye Ear and Throat Hospital | New York | New York |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Providence Newberg Medical Center | Newberg | Oregon |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | Nebraska Cancer Specialists/Oncology Hematology West PC - MECC | Omaha | Nebraska |
United States | Nebraska Methodist Hospital | Omaha | Nebraska |
United States | Oncology Associates PC | Omaha | Nebraska |
United States | Stanford Cancer Institute Palo Alto | Palo Alto | California |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Thomas Jefferson University Hospital | Philadelphia | Pennsylvania |
United States | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania |
United States | UPMC-Shadyside Hospital | Pittsburgh | Pennsylvania |
United States | Providence Portland Medical Center | Portland | Oregon |
United States | Providence Saint Vincent Medical Center | Portland | Oregon |
United States | University of California Davis Comprehensive Cancer Center | Sacramento | California |
United States | Stanford Cancer Center South Bay | San Jose | California |
United States | LSU Health Sciences Center at Shreveport | Shreveport | Louisiana |
United States | Avera Cancer Institute | Sioux Falls | South Dakota |
United States | Sanford Cancer Center Oncology Clinic | Sioux Falls | South Dakota |
United States | Sanford USD Medical Center - Sioux Falls | Sioux Falls | South Dakota |
United States | Memorial Medical Center | Springfield | Illinois |
United States | Southern Illinois University School of Medicine | Springfield | Illinois |
United States | MD Anderson in Sugar Land | Sugar Land | Texas |
United States | Smilow Cancer Hospital Care Center-Trumbull | Trumbull | Connecticut |
United States | Banner University Medical Center - Tucson | Tucson | Arizona |
United States | University of Arizona Cancer Center-North Campus | Tucson | Arizona |
United States | Memorial Sloan Kettering Nassau | Uniondale | New York |
United States | University of Kansas Hospital-Westwood Cancer Center | Westwood | Kansas |
Lead Sponsor | Collaborator |
---|---|
NRG Oncology | National Cancer Institute (NCI) |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient-reported neck and shoulder function (Phase II/III) | Will be evaluated and compared using the Neck Dissection Impairment Index (NDII), a 10-item tool between the two treatment arms. It is assumed that a 7.5-point (change from Baseline to 6 months) between arm difference is clinically meaningful. The hypothesis of no between-arm difference in 6-month NDII scores will be tested using the ANCOVA model at one-sided significance level of 0.10. Point estimates and 95% confidence intervals (CIs) for the mean NDII scores at 6 months for each treatment arm and for the between-arm difference at 6-months based on the proposed model will be provided. | From Baseline (Before surgery) to 6 months post-surgery | |
Primary | Disease-Free Survival | An event for disease-free survival is local recurrence, regional recurrence, distant metastasis, or death due to any cause. Disease-free survival time is randomization date to the date of event or last known follow-up (censoring). Rates will be estimated using the Kaplan-Meier method and between-arm differences compared using the log-rank test. | From randomization to local/regional recurrence, distant metastasis, or death due to any cause, whichever comes first, assessed up to 11 years | |
Secondary | Overall Survival | An event for overall survival is death due to any cause. Overall survival time is randomization date to date of event or last known follow-up (censoring). Rates will be estimated using the Kaplan-Meier method and between-arm differences compared using the log-rank test. | From randomization to death due to any cause, assessed up to 11 years | |
Secondary | Loco-regional Failure | An event for local-regional failure is local or regional recurrence. Local-regional failure time is randomization date to date of event, precluding event, or last known follow-up (censoring). Rates will be estimated using the cumulative incidence method and between arm differences compared using cause-specific log-rank test. | From the time of randomization to the date of failure, date of precluding event, or last known follow-up date, assessed up to 11 years | |
Secondary | Distant metastasis | An event is the occurrence of distant metastasis. Distant metastasis time is randomization to date of event, precluding event, or last known follow-up (censoring). Rates will be estimated using the cumulative incidence method and between-arm differences compared using cause-specific log-rank test. | From the time of randomization to the date of distant metastasis, date of precluding event, or last known follow-up date, assessed up to 11 years | |
Secondary | Patient-reported shoulder-related QOL, function impairment and disability | Patient reported using Abbreviated Disabilities of the Arm, Shoulder, and Hand (QuickDASH) with scores of 0-100. A higher score indicates greater disability. | Baseline, 3 weeks, 3, 6, 12 months post-surgery. Analysis occurs at the same time as the primary endpoint. | |
Secondary | General quality of life | Will be measured using the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) to measure Functional Assessment of Cancer Therapy-Head and Neck-Trial Outcome Index (FACT-TOI) scores on a scale from 0-96. A higher score indicates better quality of life. | Baseline, 3 weeks, 3, 6, 12 months post-surgery. Analysis occurs at the same time as the primary endpoint. | |
Secondary | Nodal metastasis detection rate | Defined as the proportion of patients with pathologic positive nodes using the pathology results. | During surgery. Analysis occurs at the same time as the primary endpoint. | |
Secondary | Pathologic false omission rate | Measured within the sentinel lymph node biopsy (SLN) arm only. Defined as the proportion of patients with false negative results among negative SLN patients. | During surgery. Analysis occurs at the same time as the primary endpoint. | |
Secondary | Post-surgery patient-reported outcome | Measured by NDII in low-risk oral cavity squamous cell carcinoma patients using ANCOVA comparison model. | At 6 months post-surgery. Analysis occurs at the same time as the primary endpoint. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03650699 -
Biofeedback Rehabilitation to Improve Speaking and Eating in Public
|
N/A | |
Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
Terminated |
NCT03053960 -
Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer
|
||
Recruiting |
NCT05876247 -
Articulatory Adaptation Following Oral Cancer Treatment
|
||
Completed |
NCT03618654 -
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
|
Early Phase 1 | |
Recruiting |
NCT04801472 -
Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)
|
N/A | |
Recruiting |
NCT04858269 -
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03529604 -
Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients
|
||
Completed |
NCT03028766 -
WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer
|
Phase 1 | |
Recruiting |
NCT05681039 -
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
|
Phase 2 | |
Completed |
NCT03510390 -
Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation
|
N/A | |
Recruiting |
NCT05578170 -
Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma
|
||
Recruiting |
NCT05950737 -
Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience
|
N/A | |
Recruiting |
NCT03727594 -
Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
|
||
Terminated |
NCT02582008 -
Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
|
Early Phase 1 | |
Recruiting |
NCT05749042 -
A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT06097468 -
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04892875 -
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03784066 -
Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03381183 -
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
|
Phase 1 |